Thomas Ciulla MD PC

[ad_1] Just published @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is clinical reality. 4 therapies delivered SC are in #clinicaltrials: a corticosteroid, a TKI, a #genetherapy & a virus-like drug conjugate. https://t.co/ZkPAafykHA [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …

[ad_1] RT @AAOjournal: In macular edema due to retinal vein occlusion, there are important relationships between best corrected visual acuity and… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinaToday: Research continues to enhance our understanding of the correlations between these #OCT biomarkers, baseline BCVA, & visual… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: With potential approval of 1st “dry” #AMD treatments, we just published a timely review of molecular #genetics in 5 pat… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] It means a lot to be recognized by colleagues. I am honored to be named a “2022 Top Doctor”. Very grateful to work with so many talented colleagues and team members, who work hard on a daily basis, towards the collective goal of fighting …

[ad_1] RT @OphthTimes: Triamcinolone acetonide injectable suspension was launched recently as the first and only therapy approved by the FDA for u… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinalPhys: Suprachoroidal Drug Delivery Considered Viable by Retina MDs https://t.co/21AzDLh0sG https://t.co/Pde1WhC1ab [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.